149 related articles for article (PubMed ID: 16824187)
21. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation.
Li-Saw-Hee FL; Blann AD; Lip GY
Stroke; 2000 Apr; 31(4):828-33. PubMed ID: 10753983
[TBL] [Abstract][Full Text] [Related]
22. Is an advanced age an additive risk factor to the prothrombotic or hypercoagulable state in atrial fibrillation?
Roldán V; Marín F; García A; Tello-Montoliu A; Lip GY
Int J Cardiol; 2006 Jun; 110(2):265-6. PubMed ID: 16316692
[No Abstract] [Full Text] [Related]
23. Active FXI Can Independently Predict Ischemic Stroke in Anticoagulated Atrial Fibrillation Patients: A Cohort Study.
Ząbczyk MT; Hanarz M; Malinowski KP; Pociask E; Butenas S; Gajos G; Undas A
Thromb Haemost; 2022 Aug; 122(8):1397-1406. PubMed ID: 35158400
[TBL] [Abstract][Full Text] [Related]
24. The association of coagulation and atrial fibrillation: a systematic review and meta-analysis.
Tilly MJ; Geurts S; Pezzullo AM; Bramer WM; de Groot NMS; Kavousi M; de Maat MPM
Europace; 2023 Feb; 25(1):28-39. PubMed ID: 35942591
[TBL] [Abstract][Full Text] [Related]
25. Endogenous t-PA-antigen is an independent predictor of adverse cardiovascular events and all-cause death in patients with atrial fibrillation.
Freynhofer MK; Draxler DF; Gruber SC; Bruno V; Höchtl T; Fellner B; Jakl-Kotauschek G; Wojta J; Pabinger-Fasching I; Huber K; Ay C
J Thromb Haemost; 2013 Jun; 11(6):1069-77. PubMed ID: 23557188
[TBL] [Abstract][Full Text] [Related]
26. Von Willebrand factor and ADAMTS13 plasma in older patients with high CHA2DS2-VASc Score with and without atrial fibrillation.
Zhang F; Yang XC; Jia XW; Tang XH; Wang Z; Wang ZQ
Eur Rev Med Pharmacol Sci; 2017 Nov; 21(21):4907-4912. PubMed ID: 29164570
[TBL] [Abstract][Full Text] [Related]
27. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment.
Lip GY; Lowe GD; Rumley A; Dunn FG
Br Heart J; 1995 Jun; 73(6):527-33. PubMed ID: 7626351
[TBL] [Abstract][Full Text] [Related]
28. Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation.
Roldán V; Marín F; García-Herola A; Lip GY
Thromb Res; 2005; 116(4):321-5. PubMed ID: 16038717
[TBL] [Abstract][Full Text] [Related]
29. Association Between Vascular Cell Adhesion Molecule 1 and Atrial Fibrillation.
Willeit K; Pechlaner R; Willeit P; Skroblin P; Paulweber B; Schernthaner C; Toell T; Egger G; Weger S; Oberhollenzer M; Kedenko L; Iglseder B; Bonora E; Schett G; Mayr M; Willeit J; Kiechl S
JAMA Cardiol; 2017 May; 2(5):516-523. PubMed ID: 28355442
[TBL] [Abstract][Full Text] [Related]
30. Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence.
Danese E; Montagnana M; Cervellin G; Lippi G
Ann Med; 2014 Sep; 46(6):364-71. PubMed ID: 24863960
[TBL] [Abstract][Full Text] [Related]
31. Plasma levels of nitrite/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation.
Minamino T; Kitakaze M; Sato H; Asanuma H; Funaya H; Koretsune Y; Hori M
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3191-5. PubMed ID: 9409310
[TBL] [Abstract][Full Text] [Related]
32. Effects of radiofrequency catheter ablation of atrial fibrillation on soluble P-selectin, von Willebrand factor and IL-6 in the peripheral and cardiac circulation.
Kornej J; Dinov B; Blann AD; Rolf S; Arya A; Schmidl J; Husser D; Hindricks G; Bollmann A; Lip GY
PLoS One; 2014; 9(11):e111760. PubMed ID: 25390649
[TBL] [Abstract][Full Text] [Related]
33. Prothrombotic markers in atrial fibrillation: what is new?
Al-Saady NM; Sopher M
Eur Heart J; 2001 Sep; 22(18):1635-9. PubMed ID: 11511115
[No Abstract] [Full Text] [Related]
34. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?
Go AS; Hylek EM; Chang Y; Phillips KA; Henault LE; Capra AM; Jensvold NG; Selby JV; Singer DE
JAMA; 2003 Nov; 290(20):2685-92. PubMed ID: 14645310
[TBL] [Abstract][Full Text] [Related]
35. Left atrial endocardial dysfunction and platelet activation in patients with atrial fibrillation and mitral stenosis.
Luo ZQ; Hao XH; Li JH; Dai J; Liu KY; Lai YQ
J Thorac Cardiovasc Surg; 2014 Nov; 148(5):1970-6. PubMed ID: 24412254
[TBL] [Abstract][Full Text] [Related]
36. [Effect of diabetes mellitus in recovery and maintenance of sinus rhythm in patients with persistent atrial fibrillation].
Potpara T; Marinković-Erić J; Grujić M; Radojković-Cirović B; Vujisić-Tesić B; Petrović M
Srp Arh Celok Lek; 2002; 130(5-6):189-92. PubMed ID: 12395441
[TBL] [Abstract][Full Text] [Related]
37. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation.
Gustafsson C; Blombäck M; Britton M; Hamsten A; Svensson J
Stroke; 1990 Jan; 21(1):47-51. PubMed ID: 2105543
[TBL] [Abstract][Full Text] [Related]
38. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation.
Conway DS; Buggins P; Hughes E; Lip GY
Am J Cardiol; 2004 Jun; 93(11):1368-73, A6. PubMed ID: 15165916
[TBL] [Abstract][Full Text] [Related]
39. Immunothrombosis and new-onset atrial fibrillation in the general population: the Rotterdam Study.
Tilly MJ; Geurts S; Donkel SJ; Ikram MA; de Groot NMS; de Maat MPM; Kavousi M
Clin Res Cardiol; 2022 Jan; 111(1):96-104. PubMed ID: 34559294
[TBL] [Abstract][Full Text] [Related]
40. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE).
Tsai AW; Cushman M; Rosamond WD; Heckbert SR; Tracy RP; Aleksic N; Folsom AR
Am J Med; 2002 Dec; 113(8):636-42. PubMed ID: 12505113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
